Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 1(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02557321Phase 1Unknown

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Role: lead

NCT02693067Phase 1Unknown

A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver

Role: lead

NCT00986661Phase 1Unknown

A Study to Assess PV-10 Chemoablation of Cancer of the Liver

Role: lead

NCT02288897Phase 3Terminated

PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Role: lead

NCT01260779Unknown

Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors

Role: lead

All 5 trials loaded